OPNT - Opiant Pharmaceuticals, Inc.
| Previous Close | 14.50 |
| Open | 14.36 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 14.36 - 15.35 |
| 52 Week Range | 12.02 - 32.28 |
| Volume | 11,642 |
| Avg. Volume | 18,576 |
| Market Cap | 58.668M |
| Beta (3Y Monthly) | 0.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.94 |
| Earnings Date | Mar 14, 2018 - Mar 19, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.00 |
- Simply Wall St.•13 days ago
Should You Take Comfort From Insider Transactions At Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is not uncommon to see companies Read More...
- ACCESSWIRE•18 days ago
LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index
LOS ANGELES, CA / ACCESSWIRE / February 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2019. Again. We have always held the belief that our industry ...
- Zacks Small Cap Research•last month
OPNT: Acquires Drinabant for Acute Cannabinoid Overdose…
On December 26, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced the acquisition of drinabant, a novel CB-1 receptor antagonist, for the treatment of acute cannabinoid overdose (ACO). Opiant will pay Sanofi an upfront payment of $500,000 and will be responsible for all development and commercialization activities. ACO in adults, which typically occurs from the ingestion of marijuana edibles or the use of synthetic cannabinoids, can result in anxiety, nausea, agitation, and hallucinations.
- GlobeNewswire•2 months ago
Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi
Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it has entered into an exclusive global licensing agreement with Sanofi (SNY) for the development and commercialization of drinabant for the treatment of acute cannabinoid overdose (ACO). Opiant intends to develop drinabant, a cannabinoid CB-1 receptor antagonist, as an injectable for administration in an emergency department setting.
- GlobeNewswire•2 months ago
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent
SANTA MONICA, Calif., Dec. 24, 2018 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for.
- Simply Wall St.•3 months ago
Does Opiant Pharmaceuticals Inc’s (NASDAQ:OPNT) CEO Salary Reflect Performance?
Roger Crystal has been the CEO of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) since 2009. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth Read More...
- Insider Monkey•3 months ago
Granite Point Capital’s Returns, AUM, and Holdings
Warren Lammert founded Granite Point Capital, a long/short hedge fund with a focus on small-cap companies, in January 2004. The fund is headquartered in Boston, Massachusetts, and Mr. Lammert is its portfolio manager. Prior to launching his own fund, Warren Lammert honed his investment acumen for 14 years at Janus Capital Management LLC as a […]
- Zacks Small Cap Research•3 months ago
OPNT: Data from Phase 2 Study of OPNT001 in Bulimia Nervosa in 1Q19…
On November 5, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced that the last patient has completed their last visit in the Phase 2 trial of OPNT001, a naloxone nasal spray, in bulimia nervosa (BN). BN is a serious and potentially life-threatening eating disorder characterized by a cycle of binge eating and purging. BN affects approximately 1-2% of the adult population with 80% of those affected being female.
- Zacks Small Cap Research•5 months ago
OPNT: Contract with BARDA to Support Develop of OPNT003…
On September 20, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced it has entered into a $4.6 million contract with the Biomedical Advanced Research and Development Authority (BARDA), which is part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response. OPNT003 is a nasally administered formulation of nalmefene, a potent and long-acting opioid antagonist that is currently being developed as a treatment for opioid overdose. The BARDA contract is designed to cover those expenses that are not covered by the previously announced $7.4 million grant from the National Institute on Drug Abuse (NIDA).
- Benzinga•5 months ago
The Daily Biotech Pulse: Syndax Lung Cancer Trial Disappoints, Gemphire To Trim Workforce, Opiant's Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Sept. 25) Abbott Laboratories (NYSE: ABT ) Aldeyra Therapeutics ...
- Benzinga•5 months ago
The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 20.) Abbott Laboratories (NYSE: ABT ) Acceleron ...
- Simply Wall St.•5 months ago
How Should You Think About Opiant Pharmaceuticals Inc’s (NASDAQ:OPNT) Risks?
If you own shares in Opiant Pharmaceuticals Inc (NASDAQ:OPNT) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...
